Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesEarnAISquareMore
Broadcom CEO: AI growth potential far exceeds M&A returns

Broadcom CEO: AI growth potential far exceeds M&A returns

格隆汇格隆汇2026/06/05 01:31
Show original
Glonghui, June 5 — Broadcom CEO Hock Tan stated that the company's focus has now shifted from mergers and acquisitions to artificial intelligence, as AI offers stronger growth potential. This CEO built the chip giant through a series of acquisitions. At the Bloomberg Technology conference held in San Francisco on Thursday, Tan said that AI revenue is soaring, which reduces the appeal of external deals. “I look around—what can I buy that comes close to that level?” he said. He also noted that acquisitions are a distraction for both the company and its customers. According to Tan, market demand for AI infrastructure is almost insatiable. At Broadcom, Tan has made a significant pivot toward the AI market. The California-based company, headquartered in Palo Alto, sells network chips and custom accelerators used in developing and operating AI models. He expects this business to generate over 100 billion dollars in revenue in the 2027 fiscal year.
0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

Competition in US oral weight-loss drugs intensifies! Eli Lilly (LLY.US) Foundayo captures 30% of new patients, narrowing Novo Nordisk's (NVO.US) first-mover advantage

Eli Lilly stated on Monday that its oral weight-loss drug, Foundayo, has captured over 30% of the market share among new patients in the US oral obesity treatment market, narrowing the early lead achieved by Danish competitor Novo Nordisk with its Wegovy oral tablets.

智通财经2026/09/15 03:21
Competition in US oral weight-loss drugs intensifies! Eli Lilly (LLY.US) Foundayo captures 30% of new patients, narrowing Novo Nordisk's (NVO.US) first-mover advantage